| Robert Lr Gibbs, MD | |
|
24325 Crenshaw Blvd, # 283, Torrance, CA 90505-5349 | |
| (424) 777-6642 | |
| (877) 223-4535 |
| Full Name | Robert Lr Gibbs |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 26 Years |
| Location | 24325 Crenshaw Blvd, Torrance, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043326366 | NPI | - | NPPES |
| 1093019036 | Other | CA | NPI GROUP |
| Facility Name | Location | Facility Type |
|---|---|---|
| Los Angeles Community Hospital | Los angeles, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Er Physicians Medical Group Inc | 6406008499 | 3 |
News Archive
Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that results from a landmark, international Phase 3 study of the long-term safety and nutritional benefits of liprotamase for the treatment of pancreatic insufficiency in patients with cystic fibrosis (CF) will be presented at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) being held October 15-17, 2009 in Minneapolis, Minnesota.
Toumaz Limited (AIM: TMZ,) has established a new joint venture with Dr. Patrick Soon-Shiong's company California Capital Equity LLC (‘CCE'), to expand the commercialisation and distribution of the Sensium™ Digital Plaster. The joint venture, which is named "Toumaz US LLC", will be headquartered in San Diego, California, and will sell and distribute the Sensium™ Digital Plaster in North America and Worldwide.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
Teva Pharmaceutical Industries Ltd. announced today the commercial launch of Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same as the sanofi-aventis U.S. allergy treatment Allegra-D® 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) Extended-Release Tablets. Teva's product is an alternative to the brand product, which had annual sales of approximately $293 million in the United States for the twelve months that ended June 30, 2009, based on IMS sales data.
› Verified 6 days ago
| Entity Name | California Hospitalists Emergency Physicians Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760648539 PECOS PAC ID: 5193886505 Enrollment ID: O20081203000866 |
News Archive
Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that results from a landmark, international Phase 3 study of the long-term safety and nutritional benefits of liprotamase for the treatment of pancreatic insufficiency in patients with cystic fibrosis (CF) will be presented at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) being held October 15-17, 2009 in Minneapolis, Minnesota.
Toumaz Limited (AIM: TMZ,) has established a new joint venture with Dr. Patrick Soon-Shiong's company California Capital Equity LLC (‘CCE'), to expand the commercialisation and distribution of the Sensium™ Digital Plaster. The joint venture, which is named "Toumaz US LLC", will be headquartered in San Diego, California, and will sell and distribute the Sensium™ Digital Plaster in North America and Worldwide.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
Teva Pharmaceutical Industries Ltd. announced today the commercial launch of Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same as the sanofi-aventis U.S. allergy treatment Allegra-D® 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) Extended-Release Tablets. Teva's product is an alternative to the brand product, which had annual sales of approximately $293 million in the United States for the twelve months that ended June 30, 2009, based on IMS sales data.
› Verified 6 days ago
| Entity Name | Er Physicians Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063765907 PECOS PAC ID: 6406008499 Enrollment ID: O20121221000262 |
News Archive
Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that results from a landmark, international Phase 3 study of the long-term safety and nutritional benefits of liprotamase for the treatment of pancreatic insufficiency in patients with cystic fibrosis (CF) will be presented at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) being held October 15-17, 2009 in Minneapolis, Minnesota.
Toumaz Limited (AIM: TMZ,) has established a new joint venture with Dr. Patrick Soon-Shiong's company California Capital Equity LLC (‘CCE'), to expand the commercialisation and distribution of the Sensium™ Digital Plaster. The joint venture, which is named "Toumaz US LLC", will be headquartered in San Diego, California, and will sell and distribute the Sensium™ Digital Plaster in North America and Worldwide.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
Teva Pharmaceutical Industries Ltd. announced today the commercial launch of Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same as the sanofi-aventis U.S. allergy treatment Allegra-D® 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) Extended-Release Tablets. Teva's product is an alternative to the brand product, which had annual sales of approximately $293 million in the United States for the twelve months that ended June 30, 2009, based on IMS sales data.
› Verified 6 days ago
| Entity Name | Can Emergency Physicians Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265810006 PECOS PAC ID: 8820304462 Enrollment ID: O20150827002595 |
News Archive
Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that results from a landmark, international Phase 3 study of the long-term safety and nutritional benefits of liprotamase for the treatment of pancreatic insufficiency in patients with cystic fibrosis (CF) will be presented at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) being held October 15-17, 2009 in Minneapolis, Minnesota.
Toumaz Limited (AIM: TMZ,) has established a new joint venture with Dr. Patrick Soon-Shiong's company California Capital Equity LLC (‘CCE'), to expand the commercialisation and distribution of the Sensium™ Digital Plaster. The joint venture, which is named "Toumaz US LLC", will be headquartered in San Diego, California, and will sell and distribute the Sensium™ Digital Plaster in North America and Worldwide.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
Teva Pharmaceutical Industries Ltd. announced today the commercial launch of Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same as the sanofi-aventis U.S. allergy treatment Allegra-D® 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) Extended-Release Tablets. Teva's product is an alternative to the brand product, which had annual sales of approximately $293 million in the United States for the twelve months that ended June 30, 2009, based on IMS sales data.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Robert Lr Gibbs, MD 24325 Crenshaw Blvd, # 283, Torrance, CA 90505-5349 Ph: (424) 777-6642 | Robert Lr Gibbs, MD 24325 Crenshaw Blvd, # 283, Torrance, CA 90505-5349 Ph: (424) 777-6642 |
News Archive
Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that results from a landmark, international Phase 3 study of the long-term safety and nutritional benefits of liprotamase for the treatment of pancreatic insufficiency in patients with cystic fibrosis (CF) will be presented at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) being held October 15-17, 2009 in Minneapolis, Minnesota.
Toumaz Limited (AIM: TMZ,) has established a new joint venture with Dr. Patrick Soon-Shiong's company California Capital Equity LLC (‘CCE'), to expand the commercialisation and distribution of the Sensium™ Digital Plaster. The joint venture, which is named "Toumaz US LLC", will be headquartered in San Diego, California, and will sell and distribute the Sensium™ Digital Plaster in North America and Worldwide.
Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of its supplemental Biologics License Application (sBLA) seeking approval of LemtradaTM (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis.
Teva Pharmaceutical Industries Ltd. announced today the commercial launch of Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same as the sanofi-aventis U.S. allergy treatment Allegra-D® 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) Extended-Release Tablets. Teva's product is an alternative to the brand product, which had annual sales of approximately $293 million in the United States for the twelve months that ended June 30, 2009, based on IMS sales data.
› Verified 6 days ago
Dr. Gina L Sulmeyer, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3330 Lomita Blvd, Torrance, CA 90505 Phone: 310-517-4785 | |
Dr. Manpreet Singh, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 W Carson St, Torrance, CA 90502 Phone: 310-222-3501 Fax: 310-782-1763 | |
Ryan Gleber, MD, BS Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3330 Lomita Blvd, Torrance, CA 90505 Phone: 310-325-9110 | |
Dr. Daena Sarah Watcha, MD, MS Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 W Carson St, Torrance, CA 90502 Phone: 310-222-3501 Fax: 310-782-1763 | |
Mary Sun, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3330 Lomita Blvd, Dept Of Emergency Medicine, Torrance, CA 90505 Phone: 310-717-6381 | |
Dr. Shannon M Stacy, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3330 Lomita Blvd, Torrance Memorial Medical Center, Torrance, CA 90505 Phone: 310-325-9110 |